Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Part of paid clinical trials in Fort Wayne, Indiana.
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Study ID
- NCT03980041
- Phase
- PHASE2
- Status
- Completed
Conditions
- Advanced Cancer
- Bladder Cancer
- Solid Tumor
- Urothelial Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- IPI-549 (eganelisib) — DRUGIPI-549 (40mg QD) administered orally in 28-day cycles
- Nivolumab — DRUGNivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
- Placebos — DRUGPlacebo administered orally in 28-day cycles
Study Details
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
Key Dates
- Start date
- Sep 25, 2019
- Status verified
- Nov 2022
- Primary completion
- Nov 30, 2020
- Completion
- Nov 15, 2022
Study Design
- Enrollment
- 49 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: IPI-549 + NivolumabParticipants receive IPI-549 orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
- Active Comparator: Placebo + NivolumabParticipants receive placebo orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
Primary Outcome Measure
Objective Response Rate (ORR) per RECISTv1.1 [ Time Frame: First dosing date to date of confirmed disease progression, assessed up to 24 months ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Parkview Physicians | Fort Wayne | Indiana | 46845 | - |
| University of MD - Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | - |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | - |
| Coborn Cancer Center | Saint Cloud | Minnesota | 56303 | - |
| Montefiore Medical Center | The Bronx | New York | 10461 | - |
| Bon Secours St. Francis Cancer Center | Greenville | South Carolina | 29607 | - |
| Sarah Cannon Tennessee Oncology | Nashville | Tennessee | 37203 | - |
Find similar trials in Fort Wayne, IN
By condition
Related Studies
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado